July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Promotion of high-risk corneal graft survival via corneal UV-light crosslinking
Author Affiliations & Notes
  • Yanhong Hou
    Ophthalmology, University of Cologne, Cologne, Germany
  • Viet Nhat Hung Le
    Ophthalmology, University of Cologne, Cologne, Germany
  • Gábor Tóth
    University of Pecs, Pecs, Hungary
  • Sebastian Siebelmann
    Ophthalmology, University of Cologne, Cologne, Germany
  • Jens Horstmann
    Ophthalmology, University of Cologne, Cologne, Germany
  • Tim Gabriel
    Ophthalmology, University of Cologne, Cologne, Germany
  • Felix Bock
    Ophthalmology, University of Cologne, Cologne, Germany
  • Claus Cursiefen
    Ophthalmology, University of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships   Yanhong Hou, None; Viet Nhat Hung Le, None; Gábor Tóth, None; Sebastian Siebelmann, None; Jens Horstmann, None; Tim Gabriel, None; Felix Bock, None; Claus Cursiefen, None
  • Footnotes
    Support  German Research Foundation (DFG) FOR2240 “(Lymph)angiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye”, Cu 47/4-2 (CC), Cu 47/6-1 (CC), Cu 47/9-1 (CC) (www.for2240.de); EU COST BM1302 (FBo, CC; www.biocornea.eu); EU Horizon 2020 ARREST BLINDNESS (CC; www.arrestblindness.eu); Center for Molecular Medicine Cologne, University of Cologne (FBo, CC; www.cmmc-uni-koeln.de/home/)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3342. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yanhong Hou, Viet Nhat Hung Le, Gábor Tóth, Sebastian Siebelmann, Jens Horstmann, Tim Gabriel, Felix Bock, Claus Cursiefen; Promotion of high-risk corneal graft survival via corneal UV-light crosslinking. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3342.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate whether corneal crosslinking with riboflavin and ultraviolet light can improve graft survival in pathologically prevascularized high-risk corneal transplantation.

Methods : Suture-induced corneal neovascularization model was established in BALB/c mice as high risk recipient beds. Corneal crosslinking was performed by topical application of riboflavin solution followed by ultraviolet light illumination. Furthermore, allogeneic corneal transplantation was performed subsequently to compare the long-term graft survival between high-risk recipients with and without prior corneal crosslinking. Graft survival proportions were graded, and lymph nodes were excised for cell cytometry assay. In addition, after corneal crosslinking treatment, eyes were excised to assess the effect of corneal crosslinking on blood and lymphatic vessels, CD45+ cells, keratocytes, corneal endothelial cells and corneal thickness. Moreover, corneal defect size and regularity were examined.

Results : Corneal crosslinking using riboflavin and ultraviolet light promoted long-term graft survival significantly (n=12, p<0.05) eight weeks after allogeneic corneal transplantation and up-regulated CD4+CD25+FoxP3+ T regulatory cells (n=12, p<0.01) in high-risk eyes treated by corneal crosslinking. In addition, corneal crosslinking regressed both preexisting blood and lymphatic vessels significantly post treatment in treated group (n=5, p<0.05). Moreover, CD45+ cell count, keratocyte density and corneal thickness were significantly reduced in crosslinking treated groups after corneal crosslinking treatment (p<0.05). No visible change of corneal endothelium was observed in corneal crosslinking treated eyes (n=3, p<0.05) by adjusting corneal crosslinking procedure. Furthermore, there was no notable effect of crosslinking on corneal regularity and slight delay on corneal re-epithelialization process.

Conclusions : This study demonstrates for the first time that corneal crosslinking using riboflavin and ultraviolet in prevascularized high-risk eyes can significantly improve graft survival. In addition, corneal crosslinking is a novel method to regress preexisting corneal blood and lymphatic vessels and reduce CD45+ inflammatory cells in corneas without damaging corneal endothelium. Therefore, corneal crosslinking may be a promising novel therapy in the clinic.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.